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Summary
Background: Chemotherapy‐induced alopecia (CIA) ranks among the psychologically
most devastating effects of cancer treatment for oncological patients, with an over-
all incidence of 65%. Nowadays trichoscopy is largely employed in the diagnosis of
alopecia, but no description of CIA trichoscopic pattern is present in literature.
Aims: We want to create an organic description of CIA trichoscopic aspects.
Methods: Oncological patients candidate to chemotherapy drugs, afferent to our
trichological outpatient were studied. Anamnesis, clinical exam, clinical global pho-
tography, pull test, trichogram, and trichoscopy were conducted at the different
moments of therapeutic treatment.
Results: A definite trichoscopic pattern in the different phases of treatment was
observed. After the first 3 weeks of chemotherapy rare and scattered black dots,
broken hairs, flame hairs and pohl pinkus appeared. At the end of chemotherapy
besides the features described above, numerous thin hair in regrowth were
detected, together to rare terminal hair, scattered black dots and circle hair. Three
months after chemotherapy a progressive increase of follicular units and elongation
of the existing hair were visible.
Conclusions: We propose an description of CIA trichoscopic pattern and its evolu-
tion during the different phases of chemotherapy.
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1 | BACKGROUND
Chemotherapy‐induced alopecia (CIA) ranks among the psychologi-
cally most devastating effects of cancer treatment for oncological
patients. It negatively influences body image, sexuality, and self‐es-
teem, so that up to 8% of patients are referred to refuse chemother-
apy for the risk of hair loss.1
Nevertheless to date no fully satisfactory cure for CIA is at
hand.2 Its Overall incidence is estimated to be 65%, but its preva-
lence and severity are related to the category and the number of the
administered drugs. It is more frequent with poly‐chemotherapy if
compared to monotherapy.3
Hair‐shaft shedding may occur few days after starting
chemotherapy or, more often, after 2 weeks (anagen effluvium). If
hair loss takes place months after the beginning of the therapy, a
stop of anagen occurs with the induction of catagen and consequent
telogen (telogen effluvium).
The mitotic activity of the hair follicle in the moment of the insult is
probably the most important among factors that may influence the shed-
ding pattern.3 Up to 90% of scalp hairs are normally in anagen phase,
that explains why it is the most frequent affected area, unlike beard,
lashes, eyebrown, axillary, and pubic hair that are usually less involved.
Chemotherapy accelerates the normal transition from late anagen phase,
characterized by a lower mitotic rate, to telogen. Catagen and telogen
are mitotically inactive phases and are typically not interested.3, 4
The affected areas seem to be selective, and frontal or occipital
hairlines are more frequently involved. Most of all alopecia is
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reversible with a complete regrowth in 3‐6 months, even if texture
and color may be different after the regrowth.5 Although, rare cases
of permanent alopecia (about 20% of CIA) are reported, and it is
probably the consequence of a damage of hair‐follicle stem cells.3, 4, 6
What exposed before is related to “classic” better known anti‐
cancer drugs. Nowadays several molecularly targeted anti‐cancer
drugs have been developed. Hair loss associated to these new drugs
has an overall incidence of 14.7%, but its characteristics and mecha-
nism are different and poorly understood.4, 7
Trichoscopy is an effective, noninvasive and nonexpensive
method for scalp evaluation.
A manual dermoscope (×10 magnification) or a videodermoscope
(up to × 1000 magnification) may be used to enhance the diagnosis
of many types of alopecia. This method besides to be simple, quick,
and easy to perform, allows to make a certain diagnosis and it is use-
ful for monitoring treatment and follow‐up. Using trichoscopy a lot
of scalp biopsy could be avoided, making this technique well
accepted by patients.
Even if trichoscopy is actually largely employed in the diagnosis
of any type of scalp diseases, no description of CIA trichoscopic pat-
tern are present in literature.
Nevertheless trichoscopy plays a crucial role in CIA management;
it is useful for the individuation of specific features before, during
and after chemotherapy. Before the treatment trichoscopy, together
to trichogram, may help to evaluate the presence of a latent or prior
scalp disease.
Trichogram allows us to instantly evaluate anagen/telogen ratio.
This data associated to therapeutic protocol (molecule, number of
drugs, dose, timing, and methods of administration) let us to estimate
the onset of hair loss and the pattern of presentation. During
chemotherapic treatment, in particular after 2/3 weeks, trichogram
and trichoscopy may show follicular unit damage.
Our aim is to describe CIA trichoscopic pattern, and their modifi-
cations during the different phases of chemotherapy.
2 | MATERIALS AND METHODS
In order to describe CIA trichoscopic pattern, we studied oncological
patients candidate to chemotherapy with “traditional” drugs afferent
to our trichological outpatient.
We selected 12 women between 35 and 70 years old, affected
by breast cancer that would have been treated with 4‐6 cycles of
FEC protocol (5‐fluorouracile, epirubicine, and cyclofosfamide).
Women with other cancer localization simultaneously and/or other
chemotherapeutic drugs were excluded.
Our evaluation consisted in anamnesis with particular attention
to the presence of previous scalp diseases and the drug protocol
that was established; clinical exam; pull test; clinical global photogra-
phy and trichoscopy using Fotofinder trichoscan®; trichogram.
All these evaluations were conducted at the following times:
before the beginning of chemotherapy (T0), 3 weeks after the first
administration (T1), every month during chemotherapy and every
3 months after the end of the therapy until 1 year (T next to T1).
3 | RESULTS
All patients completed the treatment and the evaluations.
3.1 | T0 evaluations
No patients referred previous scalp diseases, pull test was negative
in the 100% of patients. Trichogramm showed anagen hair >90%.
Seventy per cent had a normal trichoscopic pattern, but in the
30% of patients, trichoscopy showed anisotrichya, hair miniaturiza-
tion, and density reduction.
3.2 | T1 evaluations
Pull test was positive with hair in dystrophic anagen phase. Tri-
chogramm showed 70%‐100% dystrophic anagen bulb hair.
Rare and scattered trichoscopic signs appeared. They consisted
in black dots (67% of patients), broken hairs (8% of patients), excla-
mation marks (42% of patients), flame hairs (56% of patients) and
pohl pinkus (56% of patients), a certain grade of miniaturization was
present in 100% of patients (Figures 1 and 2).
3.3 | T > 1 evaluations
Pull test was positive. Trichogramm showed 70%‐100% dystrophic
anagen bulb hair.
Trichoscopic evaluations during the following months showed
sporadic yellow dots and yellow 3D dots (75% of patients), some
thin, depigmented and scattered regrowing hair (100% of patients),
in the form of circle hair (33% of patients), pigtail (42% of patients),
vellus‐like hair (92% of patients; Table 1).
At the end of chemotherapy besides the features described
above, numerous thin hair in regrowth with variable length and cal-
iber and variously pigmented were detected. Rare terminal hair could
be seen, and scattered black dots may remain, but circle hair was
the most characteristic feature (Figure 3).
Three months after the end of chemotherapy trichogram showed
an increase in anagen hair, a reduction or disappearance of dys-
trophic anagen hair and absence of telogen hair.
Trichoscopy showed a progressive increase in active follicular
units (that were previously empty) and elongation of the existing hair
was visible with trichoscopy. At the emergence from follicular ostia
regrowing hair is usually nonpigmented; we observed that after few
millimeters in length hair begins to be pigmented, assuming a bicolor
appearance, being white at the tips and variously pigmented at the
basis (Figure 4).
Eight percent of patients’ new hair appeared different than
before, becoming hyperpigmented and thicken (56%) or thinner
(44%), a different pigmentation was observed in the 80% of cases
(Figure 5).
These changes normally last just until one year after the end of
the treatment, after this time they come back to prechemotherapy
aspect.
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Nevertheless about 20% of all patients, reported a reduction in
the distribution of follicular units and the persistence of vellus hair if
compared with the T0 state. The 50% of these subjects had anisotri-
chya, hair miniaturization and density reduction at the time of the
first evaluation, but another 50% had a normal trichoscopy.
4 | DISCUSSION
At the best of our knowledge no complete description of CIA tricho-
scopic pattern are present in literature. Just isolated trichoscopic fea-
ture are reported to be present in patients with CIA and they are
not differentiated on the basis of the chemotherapy phase.
Miteva and Tosti reported the presence of flame hair in 100% of
6 cases of chemotherapy induced hair loss, described as a type of
hair residue resulting from severe external injury to the hair shaft.8
F IGURE 1 Trichoscopy and trichogram
of the same patient before (A1, A2) and
during (B1, B2) chemotherapy. Image A1:
normal trichoscopic pattern. Image A2:
anagen hair. Image B1: Black dots, broken
hairs, sporadic yellow dots, pohl pinkus
and a circle hair could be observed. Image
B2: dystrophic anagen hair
F IGURE 2 A trichoscopic image during chemotherapy
administration. Black dots (red circles), broken hairs (green circles),
sporadic yellow dots (yellow circles), pohl pinkus (yellow arrow), and
a circle hair (blue arrow) could be observed
TABLE 1 Patients’ trichoscopic findings at T2 evaluation
Patients
Circle
hair
Pohl
pinkus
Exclamation
marks
Black
dots
Flame
hair
Density
reduction
Empty
follicles Miniaturization
Yellow
dots
Vello‐like
hairs
Pigtail
hairs
Broken
hairs
1 0 1 1 1 1 0 1 1 1 1 0 0
2 0 1 0 1 1 1 1 1 1 1 1 0
3 1 0 0 0 0 0 0 1 0 1 1 0
4 0 1 0 1 1 1 1 1 1 1 0 0
5 0 0 0 0 0 0 0 1 0 1 0 0
6 0 0 1 1 1 1 1 1 1 1 0 0
7 1 1 0 1 1 1 1 1 1 1 1 1
8 1 1 1 1 1 1 1 1 1 1 1 1
9 1 0 0 0 0 1 0 1 0 0 0 0
10 0 1 1 1 1 1 1 1 1 1 0 0
11 0 1 0 1 1 1 1 1 1 0 1 0
12 0 0 1 0 0 1 1 1 1 1 0 0
33% 58% 42% 67% 67% 75% 75% 100% 75% 92% 42% 8%
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Kowalska‐Oledzka et al9 reported black dots in 2 of 5 patients
with CIA as sign of cytotoxic and antiproliferating effects of
chemotherapeutic agents in anagen phase.
Pirmez et al10 reported the presence of exclamation marks,
coudability hairs, Pohl‐Pinkus constrictions, black dots, yellow dots,
and color changes in six patients affected by miscellaneous tumors,
but no precise times of observation were indicated.
No other feature seems to be reported.
We have conducted an organized study with the aim to evaluate
trichoscopic alterations of CIA, and to establish observation times.
Trichoscopy may indicate the grade of alopecia during the
chemotherapy, but what in our opinion is more important is
pretreatment scalp evaluation that lead to individuate hair alteration
and allows treating them. The presence of anisotrichya and rare scat-
tered yellow dots may indicate the presence of androgenetic alope-
cia. A reduction of hair density with together terminal and regrowing
hair suggests a diagnosis of telogen effluvium. If alopecia areata (AA)
is present, we will find yellow dots, exclamation mark hairs, black
dots, and broken hairs. Finally in case of alopecia areata incognita a
diffuse hair density reduction, yellow dots cluster and scattered
short hypopigmented regrowing hairs will be detached.
The previous presence of these diseases may influence the
regrowth after chemotherapy. This influence may be explained with
different mechanisms. Concerning AGA, if follicular units are already
fibrotic, they couldn't be recovered even when the drug insult is
over. Telogen effluvium could be paradoxically protective, because
telogen hair is less vulnerable to drug toxicity. AA mechanism is
more difficult to explain, but we can hypothesize that an already
damaged follicle and the loss of the immunological privilege could be
more easily stricken from chemotherapy. Moreover knowing the T0
condition could avoid a misdiagnose of permanent alopecia caused
by chemotherapy.
Among the trichoscopic pattern we observed, there are some
that deserve a particular attention and discussion (Figure 6).
Broken hairs, detected at the beginning of chemotherapy, mimic
exclamation marks that are usually associated to AA. But these ones
are shorter, signal of an hair damage just after the emergency from
the follicular ostium.
Exclamation marks are present in the same phase. They are
expression of a progressive reduction of follicular mitotic activity
without ongoing in telogen. This is an important difference with
exclamation marks present in AA, which are associated to the begin-
ning of telogen phase.
Flame hair, also observed by Miteva and Tosti8 results from the
disruption, fragmentation, and multifocal pigmentation of the hair
shaft at the emergency of the follicular ostium.
The specific trichoscopic pattern of flame hair could be explained
if we consider that the melanin‐producing and transporting pigmen-
tary unit is one of the principal targets of chemotherapy toxicity.
F IGURE 3 This figure shows the phase of regrowth: a lot of
circle hair and vellus hair are observed
F IGURE 4 The figure shows several "black and withe hair" (A,
lower magnification; B, greater magnification). They are the sign of
progressive recovery of the damaged follicular melanocytes
F IGURE 5 This figure shows a case of a regrowth characterized
by hyperpigmented and thicken hair with a follicular encumbrance
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This lead to abnormal transfer of pigment granules to ectopic hair
pigmentary bulb locations, extrafollicular melanin incontinence, dis-
rupted formation of melanosomes, and inhibition of melanosome
transfer into precortical keratinocytes.11, 12
In our opinion, these alterations could explain the trichoscopic
image of flame hair as a dispersion of melanin around the damaged
hair follicle because of a morphological cortical disorganization asso-
ciated to a laxity of hair medullar cells. This leads to a structural dis-
ruption of hair shaft, which appears fray, producing the flame image.
It is interesting to distinguish flame hair observed in CIA, due to
the direct cytotoxic effect of the drugs on the matrix cells, from the
same sign frequently detected in trichotillomania, which is associated
to a mechanical injury to anagen hair. Moreover, flame hair of tri-
chotillomania has a pulled‐back aspect, while in CIA it appears fray.8
Pohl pinkus is consequence of the alternation of reduction and
increase in keratinocyte proliferation activity, which leads to the
development of constrictions and expansions along the hair shaft.
Which means that hair follicle is not destroyed by drug toxicity. This
feature is present all along the treatment phases. It remembers pseu-
domoniletrix present in patients with AA, but here the internodal
tract is longer. Its pathogenesis is similar to the one of exclamation
marks, but in this case, the damage is not too severe to arrest follic-
ular mitotic activity, so that after a period of reduced proliferation, it
is able to regrow.
Scattered yellow dots appear after the first weeks of chemother-
apy, and they are the expression of a retarded anagen phase. In other
words, they represents the delayed return in anagen of the hair that
were in catagen or in telogen at the moment of the drug insult.
Circle hair, pigtail, and vellus‐like hair are visible during a pro-
longed chemotherapy. They are expression of thin regrowing anagen
hair. Circle hair differs from pigtail because it has the same caliber all
along the hair shaft, so that it is able to form a complete circle.
Whereas pigtail is thicker at the ostium, and it became more and
more thin toward the tip.
Concerning postchemotherapy phase, about 3 months after the
last drug administration, circle hair, vellus‐like hair and some terminal
hair are detachable, and these hairs will reconstitute the previous
assets. Hair pigmentation results delayed, in fact as shown in Figure 4
at the emergence from the follicular ostia hair appeared white. After
several weeks we detached bicolor hair (white at the tips and pig-
mented at the basis). We called these hairs “black and white hair.”
We hypothesize that this observation is the result of a reactivation
of follicular melanocytes, which have been damaged, but not
destroyed by drug insult. It is interesting to point out the differences
with AA. Indeed it is characterized by the presence of with vellus‐
like hair during the recovering phase of the disease that are destined
to complete the hair‐cycle, to fall, and then to be replaced by pig-
mented terminal hair.11–13 Differently in CIA it is not necessary a
whole hair cycle to reestablish pigmentation.
After 6 months/1 year the number of terminal hair and follicular
units increase. Twenty percent of all patients doesn't show this
improvement and they still present circle hair, vellus‐like hair, and
just few terminal hair, in particular at the androgen‐dependent scalp
areas. The 50% of these patients had no sign at T0 evaluation. In
regards to this last observation, we hypothesize that some women
who had no sign at T0 could have a latent FPHL condition that was
revealed after drug insult; another mechanism could be the damage
of hair‐follicle stem cells.3, 4, 6
Finally, we observed that at T0 30% of patients presents with
anisotrichya, hair miniaturization and density reduction, but at the
end of our evaluation just 20% of patients had these trichoscopic
signs. Among this 20%, just 50% of patients had trichoscopic alter-
ation at T0. Standing to this observation from 10% to 20% of sub-
jects had a trichoscopic aspect better than the one before
chemotherapy. The mechanism at the basis of this observation
remains unknown, but a damage‐response strategy development is
reported in damaged hair follicles,4 and we suppose that it could
have a role. Obviously other observations and reports are needed.
F IGURE 6 Some of the most typical
CIA trichoscopical findings: pig tail hair (A),
ingrown circle hair (F), flame hair (B, C, and
D white arrow), comma hair (D, red arrow),
yellow 3D dot (D, yellow arrow), pohl
pinkus (E)
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5 | CONCLUSIONS
This study wanted to produce an description of CIA trichoscopic
pattern and its evolution during the different phases, in order to
indicate which are the most important moments that have to be
monitored. Prechemotherapy evaluation showed a normal tricho-
scopical aspect in the 70% of patients. During chemotherapy black
dots, broken hairs, exclamation marks, flame hairs, pohl pinkus, circle
hair, pigtail, and vellus‐like hair were detached with different times
of presentation. After chemotherapy administration 80% of patients
presented a complete hair regrowth. More studies have to be con-
ducted to better characterize this type of hair loss, and continuous
attention must be paid to the effects of new but also old drugs.
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